Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The MPN PROGRESSion Registry: A Retrospective and Prospective Observational Study Collecting Patient-Reported Outcomes, Electronic Health Records, and Claims Data to Track Symptoms, Treatments, and Disease Progression in Individuals Diagnosed With Myeloproliferative Neoplasms (MPNs).

NCT07362225 is registered in ClinicalTrials.gov with MPN Research Foundation as lead sponsor.

NCT NCT07362225
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07362225 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The MPN PROGRESSion Registry: A Retrospective and Prospective Observational Study Collecting Patient-Reported Outcomes, Electronic Health Records, and Claims Data to Track Symptoms, Treatments, and Disease Progression in Individuals Diagnosed With Myeloproliferative Neoplasms (MPNs).
Lead sponsor
MPN Research Foundation
Phase
Observational
Overall status
Recruiting
Start date
September 26, 2025
Completion date
September 8, 2035
Enrollment
5,000 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

accelerated phase mpn, accelerated phase myeloproliferative neoplasm, agnogenic myeloid metaplasia, blast phase mpn, blast phase myeloproliferative neoplasm, chronic idiopathic myelofibrosis, essential thrombocythemia (et), et (essential thrombocythemia), idiopathic myelofibrosis, mds/mpn crossover syndromes, mf, mpn, mpn (myeloproliferative neoplasms), mpn-associated myelofibrosis, myelofibrosis, myelofibrosis (mf), myelofibrosis (pmf), myelofibrosis due to and following polycythemia vera, myelofibrosis transformation in essential thrombocythemia, myelofibrosis with high molecular risk mutations, myelofibrosis, post et, myelofibrosis, post pv, myelofibrosis, primary, myelofibrosis; primary myelofibrosis; post-polycythemia vera myelofibrosis; post-essential thrombocythemia myelofibrosis, myelofibrosis，mf, myeloproliferative disorder, myeloproliferative disorders, myeloproliferative disorders (mpd), myeloproliferative neoplasm with 10% blasts or higher, myeloproliferative neoplasm(mpn)-associated myelofibrosis, myeloproliferative neoplasm, not otherwise specified, myeloproliferative neoplasm, unclassifiable, myeloproliferative neoplasms, myeloproliferative neoplasms (mpns), polycythemia vera, polycythemia vera (pv), post-essential thrombocythemia myelofibrosis, post-essential thrombocythemia myelofibrosis (pet-mf), post-essential thrombocythemia myelofibrosis (post-et mf), post-essential thrombocythemia myelofibrosis(post-et mf), post-et mf, post-polycythemia vera myelofibrosis, post-polycythemia vera myelofibrosis (post-pv mf), post-polycythemia vera myelofibrosis (ppv-mf), post-polycythemia vera myelofibrosis(post-pv mf), post-pv mf, pre-fibrotic myelofibrosis, primary myelofibrosis (mf), primary myelofibrosis (pmf), secondary myelofibrosis, secondary myelofibrosis (post-polycythemia vera myelofibrosis, post-essential thrombocythemia myelofibrosis), secondary myelofibrosis in myeloproliferative disease, thrombocythemia myelofibrosis (pet-mf), thrombocythemia, essential, thrombocythemia, hemorrhagic